Reuven Agami

Reuven Agami (born 16 December 1965) is a Dutch cancer researcher. He is a professor of Oncogenomics at Erasmus University Rotterdam and head of the section of Oncogenomics at the Netherlands Cancer Institute-Antoni van Leeuwenhoekziekenhuis.

Career

Agami was born in Herzliya Israel on 16 December 1965. He studied medical biology at the University of Tel Aviv. Agami subsequently moved to the Weizmann Institute of Science (WIS) in Israel to obtain his master's degree in the Department of Biophysics studying spliced leader RNA in Leishmania parasites. Subsequently, he moved to the Department of Molecular Genetics at the WIS where he obtained his Ph.D. in 1999 under Yosef Shaul with a thesis titled: “Cell cycle and apoptosis control induced by the tyrosine kinase c-Abl”. Agami then moved to the Netherlands and was a post-doc under René Bernards at the Netherlands Cancer Institute-Antoni van Leeuwenhoekziekenhuis to study p53-independent DNA damage responses.

From 2001 to 2005 Agami was an assistant professor at the Division of Tumor Biology Netherlands Cancer Institute-Antoni van Leeuwenhoekziekenhuis. His research brought together his expertise in RNA and cancer by developing new technologies in RNA interference (RNAi) and microRNAs (miRNAs).[1]

From 2005 to 2008 Agami was appointed associate professor at the Division of Tumor Biology Netherlands Cancer Institute-Antoni van Leeuwenhoekziekenhuis. In this period, he further expanded his scientific interest to the regulation of miRNA function by RNA binding proteins.

From 2008 to 2013 Agami became the head of the Division of Gene Regulation at the Netherlands Cancer Institute-Antoni van Leeuwenhoekziekenhuis. During this period, he broadened his scientific interest in the regulation of gene expression by Alternative polyadenylation (APA).

From 2013 to 2017 Agami was heading the Division of Gene Regulation at the Netherlands Cancer Institute-Antoni van Leeuwenhoekziekenhuis. With the development of Ribosome profiling and CRISPR-Cas9 technologies, he further studied transcriptional Enhancers and mRNA translation, mostly focusing on enhancerRNAs and predicting metabolic changes in cancer.

Since 2017 Agami is heading the Division of Oncogenomics at the Netherlands Cancer Institute-Antoni van Leeuwenhoekziekenhuis where he investigates mistakes made during mRNA translation when cancer cells experience specific amino acid deficiencies. He aims at utilizing these findings to improve cancer immunotherapy of resistant tumors.

Since 2008 Agami is also a full Professor at the Department of Molecular Genetics at Erasmus Medical Centre Rotterdam University, The Netherlands.

Research

Agami is known for his work utilizing RNA-based and functional genomics technologies in cancer research.[2] He was the inventor of pSUPER, a plasmid-based suppression of gene expression, miRVec, a vector-based expression of miRNAs, and the expression of aberrant proteins due to Ribosomal frameshift and substitutants following IDO1-mediated Interferon gamma-induced tryptophan depletion of cancer cells by T cell attack.[3][4] His research greatly contributed to the fields of miRNAs, RNA binding proteins, Alternative cleavage and polyadenylation, non-coding RNAs, and mRNA translation. His recent work on aberrant peptides holds the potential to develop immunotherapeutic approaches to treat cancer.[5][6][7][8]

Honors and distinctions
  • In 1999, Agami was awarded a European Molecular Biology Organization (EMBO) long-term fellowship in 1999,
  • an EMBO Young investigator program (EMBO-YIP) award.[9] in 2004, and was elected an EMBO member in 2008.[10]
  • In 2001, Agami was awarded the Netherlands Cancer Institute-Antoni van Leeuwenhoekziekenhuis Prize [11] for his contributions in the field of p53-independent DNA damage responses.
  • In 2004, he was elected a member of the young Dutch royal academy of science (DJA-KNAW).[12] During his scientific career, Agami was awarded the European young investigator (EURYI) award in 2004.[13]
  • In 2007 Agami was the winner of the Dr. Joseph Steiner Prize for his contributions in the field of small RNAs and Cancer. Further, he received VIDI and VICI awards from Dutch Research Council(NWO) in 2004 and 2011, respectively[14]
  • ERC-starting award in 2008, ERC-advanced in 2012, and 2018[15]
  • In 2010 Agami was awarded the European Society for Clinical Investigation (ESCI) Prize for his contributions in the field of miRNAs and cancer.
  • In 2016 Agami was nominated a member of the Academia Europaea.[7] In 2017 he was elected a member of Oncode Institute[6]

References
  1. "How Cancers Hurt Themselves to Hurt Immune Cells More". Business News This Week. 20 January 2021.
  2. "Eight research groups Netherlands Cancer Institute to receive Dutch Cancer Society grants". Netherlands Cancer Institute.
  3. "How Cancers Hurt Themselves to Hurt Immune Cells More - Weizmann Wonder Wander - News, Features and Discoveries". Weizmann Wonder Wander. 16 December 2020.
  4. "Researchers find out what cancer cells are hungry for". Medical Xpress.
  5. "Reuven Agami Group | Oncogenomics | Netherlands Cancer Institute". Netherlands Cancer Institute.
  6. "Reuven Agami Group". Oncode Institute.
  7. "Academy of Europe: Agami Reuven". Academia Europaea.
  8. "Protein that could stop breast cancer discovered". The Hindu. 15 March 2010.
  9. "Fellowships, grants and career support – Young Investigator Programme – EMBO". 20 August 2020.
  10. "Find people in the EMBO Communities". people.embo.org.
  11. "Antoni van Leeuwenhoekprijs voor NKI-onderzoeker". Ziekenhuis.nl.
  12. "Alumni". De Jonge Akademie.
  13. "2004 : European Science Foundation". ESF.
  14. "Vici 2010 | NWO". www.nwo.nl.
  15. "2,5 miljoen ERC-subsidie voor genregulatie-onderzoek". www.avl.nl.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.